Management of Chronic Myeloid Leukemia by Advanced Practice Nurses
Evaluation of Advanced Practice Nurse's Management of Patients With Chronic Myeloid Leukemia
This study is testing how Advanced Practice Nurses can help people with Chronic Myeloid Leukemia manage their treatment and improve their quality of life.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Henri Duffaut - Avignon Academic / other |
| Locations | 1 site (Avignon) |
| Trial ID | NCT06082804 on ClinicalTrials.gov |
What this trial studies
This study evaluates the role of Advanced Practice Nurses (APNs) in managing patients with Chronic Myeloid Leukemia (CML) during the chronic phase. It focuses on optimizing treatment by addressing adverse events, ensuring treatment compliance, and assessing the quality of life of patients. The study aims to improve early detection of adverse events, which are often underreported, thereby enhancing patient care and therapeutic outcomes. Participants will receive both medical management and follow-up care from APNs.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with chronic phase CML who are eligible for oral therapy.
Not a fit: Patients with unresolved grade II or higher toxicities at the time of inclusion may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved management of CML and better quality of life for patients.
How similar studies have performed: Other studies have shown promising results with APN-led management in chronic conditions, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years old. * CML patient in chronic phase, eligible for oral therapy. * Newly diagnosed CML and/or initiating oral therapy : * Patient changing treatment for non-response or loss of therapeutic response or toxicities, on the condition that these toxicities are resolved or grade I maximum at the time of inclusion. * Newly start of oral therapy. * Patient eligible to a follow-up by an advanced practice nurse. * Patient capable to understand french and complete a questionnaire. Exclusion Criteria: * Patient that had a follow-up \> 3 months by an advanced practice nurse for CML before inclusion. * Patient changing treatment for toxicities, if these toxicities are still \> grade I at inclusion. * Patient enrolled in another interventional research protocol for CML. * Pregnant women. * Patient under legal protection, deprived of liberty or unable to be included in a research protocol.
Where this trial is running
Avignon
- Centre Hospitalier d'Avignon, Hôpital Henri Duffaut — Avignon, France (Recruiting)
Study contacts
- Principal investigator: Christine Tosello, APN — Centre Hospitalier d'Avignon, Service d'Oncologie Médicale-Hématologie Clinique
- Study coordinator: Marilyne Grinand, PhD
- Email: grinand.marilyne@ch-avignon.fr
- Phone: (+33)432759392
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.